Corline Biomedical AB OMXSTO:CLBIO:
ANNOUNCES DIRECTED SHARE ISSUE RAISING ABOUT 9.24 MSEK
SHARE ISSUE DIRECTED TO CANADIAN COMPANY KARDIUM CORP
TAKES LOAN OF 9.24 MSEK FROM KARDIUM
RECEIVES TOTAL OF ABOUT 18.5 MSEK FROM ISSUE AND LOAN
Corline Flags Share Issue Raising About SEK 9.24 Mln
Earlier from Corline Biomedical
- CLBIO: Breakthrough quarter with FDA approval, long-term deal, and capital raise set stage for growth
- Corline Biomedical Signs 10-Year Agreement With Kardium
- CLBIO: Growth depends on Kardium's US launch, with cost cuts improving results despite lower sales
- CLBIO: Corline's Q1 2025 loss widens, but US market entry and strong clinical data drive optimism
- CLBIO: 2024 saw heavy losses and restructuring, but Corline targets US growth with CHSTM-coated Globe®
Later from Corline Biomedical
- CLBIO: FDA approval, US launch, and a major 10-year deal drove a pivotal commercial breakthrough
- Corline Biomedical Q4 (Review): Case intact, but sales ramp-up needed to restore market confidence
- Corline Biomedical Q1 Result After Financial Items At SEK -2.5 Mln
Follow Corline Biomedical into a list and get an email when it puts out news.
Follow Corline Biomedical